Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for S. aureus CR-BSI
NCT05117398Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2023
- Primary completion
- Sep 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalbavancin in catheter-related bloodstream infection (CRBSI), Staphylococcus aureus infection, sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2023; status: recruiting.
02
Drugs
dalbavancin
03
Conditions
catheter-related bloodstream infection (CRBSI)Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT05117398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117398.